175 related articles for article (PubMed ID: 35932909)
1. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.
Moody TW; Ramos-Alvarez I; Jensen RT
Peptides; 2022 Oct; 156():170858. PubMed ID: 35932909
[TBL] [Abstract][Full Text] [Related]
2. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
[TBL] [Abstract][Full Text] [Related]
3. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
4. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
Moody TW; Lee L; Jensen RT
J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
[TBL] [Abstract][Full Text] [Related]
5. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
6. Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.
Moody TW; Lee L; Ramos-Alvarez I; Jensen RT
Eur J Pharmacol; 2019 Dec; 865():172735. PubMed ID: 31614143
[TBL] [Abstract][Full Text] [Related]
7. Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer.
Moody TW; Ramos-Alvarez I; Jensen RT
Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508387
[TBL] [Abstract][Full Text] [Related]
8. CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Moody TW; Nuche-Berenguer B; Moreno P; Jensen RT
J Mol Neurosci; 2015 Jul; 56(3):663-72. PubMed ID: 25761747
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
[TBL] [Abstract][Full Text] [Related]
10. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Moody TW; Ramos-Alvarez I; Moreno P; Mantey SA; Ridnour L; Wink D; Jensen RT
Peptides; 2017 Apr; 90():90-99. PubMed ID: 28153500
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.
Moody TW; Osefo N; Nuche-Berenguer B; Ridnour L; Wink D; Jensen RT
J Pharmacol Exp Ther; 2012 Jun; 341(3):873-81. PubMed ID: 22389426
[TBL] [Abstract][Full Text] [Related]
12. Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
Ouyang Q; Chen G; Zhou J; Li L; Dong Z; Yang R; Xu L; Cui H; Xu M; Yi L
Neuro Oncol; 2016 Feb; 18(2):216-26. PubMed ID: 26180082
[TBL] [Abstract][Full Text] [Related]
13. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients.
Ouyang Q; Gong X; Xiao H; Zhou J; Xu M; Dai Y; Xu L; Feng H; Cui H; Yi L
Mol Cancer; 2015 Feb; 14():21. PubMed ID: 25644759
[TBL] [Abstract][Full Text] [Related]
14. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract][Full Text] [Related]
15. Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody.
Wu Z; Fournel L; Stadler N; Liu J; Boullier A; Hoyeau N; Fléjou JF; Duchatelle V; Djebrani-Oussedik N; Agopiantz M; Ségal-Bendirdjian E; Gompel A; Alifano M; Melander O; Trédaniel J; Forgez P
Cancer Lett; 2019 Mar; 444():147-161. PubMed ID: 30583074
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
Tanizaki J; Okamoto I; Sakai K; Nakagawa K
Br J Cancer; 2011 Sep; 105(6):807-13. PubMed ID: 21847121
[TBL] [Abstract][Full Text] [Related]
17. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
Moody TW; Sancho V; di Florio A; Nuche-Berenguer B; Mantey S; Jensen RT
Peptides; 2011 Aug; 32(8):1677-84. PubMed ID: 21712056
[TBL] [Abstract][Full Text] [Related]
18. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
Zhang Y; Zhu S; Yi L; Liu Y; Cui H
Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116
[TBL] [Abstract][Full Text] [Related]
19. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
Moody TW; Berna MJ; Mantey S; Sancho V; Ridnour L; Wink DA; Chan D; Giaccone G; Jensen RT
Eur J Pharmacol; 2010 Jul; 637(1-3):38-45. PubMed ID: 20388507
[TBL] [Abstract][Full Text] [Related]
20. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
